Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
about
Conjugate vaccines for preventing meningococcal C meningitis and septicaemiaConjugate vaccines for preventing meningococcal C meningitis and septicaemiaProspects for vaccine prevention of meningococcal infectionHib Vaccines: Past, Present, and Future PerspectivesPneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Prevention of Community-Acquired Pneumonia with Available Pneumococcal VaccinesReview of meningococcal vaccines with updates on immunization in adultsInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyVaccines against meningococcal disease: current and future technologies.Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.Importance of complement source in measuring meningococcal bactericidal titers.Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescentsMeningococcal disease and the complement system.Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.Priming for immunologic memory in adults by meningococcal group C conjugate vaccination.Pneumococcal vaccination and revaccination of older adults.Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.Meningococcal disease: treatment and prevention.Meningococcal group C conjugate vaccines.Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia.Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil.Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.Conjugate vaccines.Anti-pneumococcal antibody titre measurement: what useful information does it yield?The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferioritImmunization strategies for the control of serogroup C meningococcal disease in developed countries.Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Vaccine-preventable infections in Systemic Lupus Erythematosus.Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.Expanding prevention of invasive meningococcal disease.Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.Advances with vaccination against Neisseria meningitidis.Glycoconjugate vaccines.
P2860
Q24235722-03950D1A-BCBD-4517-86EB-5D79965CCF1AQ24244951-D84D98F2-BF3B-43F4-8AF2-A7550FC422D0Q24537338-D595530B-FFAD-49B2-9B8A-DC01A83F96FCQ26767144-7DFBBC71-7C56-4D8F-8553-00B9614F25D1Q28070059-DA75E758-9C00-4085-BEFC-7198A02CF7A6Q28077703-EE3A56AC-3087-4CDC-BDFD-5A1E58179153Q28828692-AD0145C1-EF66-4CEA-B26A-9E9BE54395D6Q28972389-0DCC4FAC-5262-4C67-8965-E000E6BCA64AQ30771493-26FF0B62-0D4C-43B8-A0A4-28E5AB8A68E8Q33959308-549C951F-DDF2-458E-B568-9AC4A517E44DQ33999159-D036AD6E-5055-4848-8E15-AE196A00759FQ34004276-1DB670DB-B4EE-4BD2-B7C5-C635091A4FFFQ34376170-1DE9BA31-1AE3-45F4-9F25-041EB2E51331Q34531872-7AF68C9C-FC18-459C-A3B1-33A14A6915EEQ34720293-3CDAB8BA-7AA0-4826-A8B1-7A3B42F9E223Q34926870-35F1FBE9-F967-4508-A1FB-A45A8B9A19F8Q34975007-EE89C607-7C76-4C0F-B637-AB466758CAB7Q35013077-017355FD-DC9D-41C7-B90C-8660F1AFB3EBQ35055030-F097CF27-C8E3-4818-91D6-B64ABC61B041Q35269816-2728A5BE-C47B-45A3-928E-1CF854F42F85Q35542416-3618430E-2C5D-4927-9994-A9B7D7815827Q35554452-5620E5B0-77FB-4D3D-BEA6-95577FA25CE2Q35588006-3665502C-7B0D-4CF9-B0DF-4561281915E9Q35623292-35E5D064-F9A2-45DA-B378-967420A372DAQ36026175-26195DE8-FDA6-4CD2-80B5-11C3A83C63D0Q36391883-069E00D2-1252-44EB-89E6-106EB2B67D74Q36445558-154321FE-6DA9-421B-A2AF-825C2DE597BAQ36600323-61A765ED-0BFD-4762-8EEC-6F5F51897989Q36731011-25123BCE-C444-45B0-8D9F-823544C10DCFQ36791713-1A579568-3B11-4C6B-B2EA-F6A3A7055703Q37037419-ADB6F658-EEE5-4D88-B49B-B09968C9AD7EQ37135056-ABA027DC-2258-4639-8420-3F3BC3BFF507Q37197065-7A294535-3111-4639-9400-8B367A2CAA05Q37343744-267F23D5-E4A4-490B-900F-A4957213C3E4Q37461347-F548FE66-DC86-40ED-8613-A0062AB69BE0Q37503239-07316304-D4FB-4022-9F08-F39ADEC6A262Q37595207-560047F6-1755-4301-AED4-7B01DD2C71C4Q37857246-946F1164-35CC-48A3-BE41-EE6DE386F793Q38040527-7F26C1C5-DA83-48D6-B4F7-C225CBC00991Q38044755-A9043BD6-437D-45C9-AF6F-13B5338A96DF
P2860
Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Induction of immunologic refra ...... C polysaccharide vaccination.
@en
Induction of immunologic refra ...... C polysaccharide vaccination.
@nl
type
label
Induction of immunologic refra ...... C polysaccharide vaccination.
@en
Induction of immunologic refra ...... C polysaccharide vaccination.
@nl
prefLabel
Induction of immunologic refra ...... C polysaccharide vaccination.
@en
Induction of immunologic refra ...... C polysaccharide vaccination.
@nl
P2093
P356
P1476
Induction of immunologic refra ...... C polysaccharide vaccination.
@en
P2093
P304
P356
10.1086/515346
P407
P577
1998-09-01T00:00:00Z